1887
No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.

Novel Targets of Antimicrobial Therapies

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.
Buy this Microbiology Spectrum Article
Price Non-Member $15.00
  • Author: Sarah E. Maddocks1
  • Editors: Indira T. Kudva2, Bryan H. Bellaire3
  • VIEW AFFILIATIONS HIDE AFFILIATIONS
    Affiliations: 1: Department of Biomedical Sciences, Cardiff School of Health Sciences, Cardiff Metropolitan University, Western Avenue, Llandaff, Wales, CF5 2YB; 2: National Animal Disease Center, Agricultural Research Service, U.S. Department of Agriculture, Ames, IA; 3: Department of Veterinary Microbiology and Preventive Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA
  • Source: microbiolspec April 2016 vol. 4 no. 2 doi:10.1128/microbiolspec.VMBF-0018-2015
  • Received 23 April 2015 Accepted 17 December 2015 Published 08 April 2016
  • Sarah E. Maddocks, smaddocks@cardiffmet.ac.uk
image of Novel Targets of Antimicrobial Therapies
    Preview this microbiology spectrum article:
    Zoom in
    Zoomout

    Novel Targets of Antimicrobial Therapies, Page 1 of 2

    | /docserver/preview/fulltext/microbiolspec/4/2/VMBF-0018-2015-1.gif /docserver/preview/fulltext/microbiolspec/4/2/VMBF-0018-2015-2.gif
  • Abstract:

    Antibiotics are undoubtedly a pillar of modern medicine; their discovery in 1929 revolutionized the fight against infectious disease, instigating a worldwide decline in infection-associated mortality. Throughout the 1930s, 1940s, and 1950s the golden age of antibiotic discovery was underway with numerous new classes of antibiotics identified and brought to market. By 1962 all of our currently known families of antibiotics had been discovered, and it was a widely held belief, that humanity had conquered infectious disease. Despite varying bacterial cellular targets, most antibiotics targeted exponentially multiplying bacteria by interfering with integral processes such as peptidoglycan synthesis or ribosomal activity. The very nature of this targeted approach has driven the emergence of antibiotic-resistant bacteria.

    Methods of antibiotic identification relied solely on scientific observation, and while chemical analogues such as amoxicillin, derived from penicillin, continued to be developed, they retained the same mechanisms of action and hence the same bacterial targets. This article describes and discusses some of the emerging novel targets for antimicrobial treatments, highlighting pivotal research on which our ability to continue to successfully treat bacterial infection relies.

  • Citation: Maddocks S. 2016. Novel Targets of Antimicrobial Therapies. Microbiol Spectrum 4(2):VMBF-0018-2015. doi:10.1128/microbiolspec.VMBF-0018-2015.

References

1. Bryan J. 2011. Still going at 30: co-amoxiclav. Pharm J 286:762.
2. Belcheva A, Golemi-Kotra D. 2008. A close up view of the VraSR two-component system. J Biol Chem 283:12354–12364. [PubMed][CrossRef]
3. Boyle-Vavra S, Yin S, Sun Jo D, Montgomery CP, Duam RS. 2013. VraT/YvqF is required for methicillin resistance and activation of the VraSR a regulon in Staphylococcus aureus. Antimicrob Agents Chemother 57:83–95. [PubMed][CrossRef]
4. Utaida S, Dunman PM, Macapagal D, Murphy E, Projan SJ, Singh VK, Jayaswal RK, Wilkinson BJ. 2003. Genome-wide transcriptional profiling of the response of Staphylococcus aureus to cell-wall-active antibiotics reveals a cell-wall-stress stimulon. Microbiol 149:2719–2732. [PubMed][CrossRef]
5. Barrett JF, Goldschmidt RM, Lawrence LE, Foleno B, Chen R, Demers JP, Johnson S, Kanojia R, Fernandez J, Bernstein J, Licata L, Huang S, Hlasta DJ, Macielag MJ, Ohemeng K, Frechette R, Frosco MB, Klaubert DH, Whiteley JM, Wang L, Hoch JA. 1998. Antibacterial agents that inhibit two-component signal transduction systems. Proc Natl Acad Sci USA 95:5317–5322. [PubMed][CrossRef]
6. Roychoudhury S, Zielinski NA, Ninfa AJ, Allen NE, Jungheim LN, Nicas TI, Chakrabarty AM. 1993. Inhibitors of two-component signal transduction systems: inhibition of alignate gene activation in Pseudomonas aeruginosa. Proc Natl Acad Sci USA 90:965–969. [PubMed][CrossRef]
7. Park S, Park Y, Hahm K. 2011. The role of anti-microbial peptides in preventing multi drug-resistant bacterial infections and biofilm formation. Int J Mol Sci 12:5971–5992. [PubMed][CrossRef]
8. Xu W, Zhu X, Tan T, Li W, Shan A. 2014. Design of embedded-hybrid anti-microbial peptides with enhanced cell selectivity and anti-biofilm activity. PLoS One 9:e98935. doi:10.1371/journal.pone.0098935. [PubMed][CrossRef]
9. Fuente-Nunez C, Reffuvielle F, Haney EF, Strauss SK, Hancock REW. 2014. Broad-spectrum anti-biofilm peptide that targets a cellular stress response. PLoS Pathog 10:e1004152. doi:10.1371/journal.ppat.1004152. [PubMed][CrossRef]
10. Lo AWH, Water K, Gane PJ, Chan AWE, Steadman D, Stevens K, Selwood DL, Waksman G, Remaut H. 2014. Suppression of type 1 pillus assembly in uropathogenic Escherichia coli by chemical inhibition of subunit polymerization. J Antimicrob Chemother 69:1017–1026. [PubMed][CrossRef]
11. Kvist M, Hancock V, Klemm P. 2008. Inactivation of effluent pumps abolishes bacterial biofilm formation. App Env Microbiol 23:7376–7382. [PubMed][CrossRef]
12. Zhang L, Mah T. 2008. Invovlement of a novel efflux system in biofilm-specific resistance to antibiotics. Appl Environ Microbiol 74:7376–7382.
13. Poole K. 2005. Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 56:20–51. [PubMed][CrossRef]
14. Nairz M, Haschka D, Demetz E, Weiss G. 2014. Iron at the interface of immunity and infection. Front Pharmacol 16:152. [PubMed][CrossRef]
15. Frangipani E, Bonchi C, Minandri F, Imperi F, Visca P. 2014. Pyochelin potentiates the inhibitory activity of gallium on Pseudomonas aeruginosa. Antimicrob Agents Chemother 58:5572–5575. [PubMed][CrossRef]
16. Oglesby-Sherrouse AG, Djapgne L, Nguyen AT, Vasil AL, Vasil ML. 2014. The complex interplay of iron, biofilm formation, and mucoidy affecting antimicrobial resistance of Pseudomonas aeruginosa. Pathog Dis 70:307–320. [PubMed][CrossRef]
17. Ross-Gillespie A, Weigert M, Brown SP, Kummerli R. 2014. Gallium-mediated siderophore quenching as an evolutionary robust antibacterial treatment. Evol Med Public Health 1:18–29. [PubMed][CrossRef]
18. Kelson AB, Carnevali M, Truong-Le V. 2013. Gallium-based anti-infectives: targeting microbial iron-uptake mechanisms. Curr Opin Pharmacol 13:707–716. [PubMed][CrossRef]
19. Banin E, Lozinski A, Brady KM, Berenshtein E, Butterfield PW, Moshe M, Chevion M, Greenberg EP, Banin E. 2008. The potential of desferrioxamine-gallium as an anti-Pseudomonas therapeutic agent. Proc Natl Acad Sci USA 43:16761–16766. [PubMed][CrossRef]
20. Escaich S. 2008. Antivirulence as a new antibacterial approach for chemotherapy. Curr Opin Chem Biol 12:400–408. [PubMed][CrossRef]
21. Moayeri M, Crown D, Jiao G, Kim S, Johnson A, Leysath C, Leppla SH. 2013. Small-molecule inhibitors of lethal factor protease activity protect against anthrax infection. Antimicrob Agents Chemother 57:4139–4145. [PubMed][CrossRef]
22. Goller C, Seed PC. 2010. High-throughput identification of chemical inhibitors of E. coli group 2 capsule biogenesis as anti-virulence agents. PLoS One 5:e11642. doi:10.1371/journal.pone.0011642. [CrossRef]
23. Pacheco AR, Sperandio V. 2012. Shiga toxin in enterohaemorrhagic E. coli: regulation and novel anti-virulence strategies. Front Cell Infect Microbiol 2:81. [PubMed][CrossRef]
24. Medeiros P, Bolick DT, Roche JK, Norohna F, Pinheiro C, Kolling GL, Lima A, Guerrant RL. 2013. The micronutrient zinc inhibits EAEC strain 042 adherence, biofilm formation, virulence gene expression, and epithelial cytokines responses benefitting the infected host. Virulence 4:624–633. [PubMed][CrossRef]
25. Stubbed CJ, Duffield ML, Cooper IA, Ford DC, Gans JD, Karlyshev AV, Lingard B, Oyston PCF, de Rochefort A, Song J, Wren BW, Titball RW, Wolonsky M. 2009. Steps towards broad-spectrum therapeutics: discovering virulence-associated genes present in diverse human pathogens. BMC Genomics 10:501. [PubMed][CrossRef]
26. Njorage J, Sperandio V. 2009. Jamming bacterial communication: new approaches for the treatment of infectious disease. EMBO Mol Med 1:201–210. [PubMed][CrossRef]
27. Starkey M, Lepine F, Maura D, Bandyopadhaya A, Lesic B, He J, Kitao T, Righi V, Milot S, Tzika A, Rahme L. 2014. Identification of anti-virulence compounds that disrupt quorum-sensing regulated acute and persistent pathogenicity. PLoS Pathog 10:e1004321. doi:10.1371/journal.ppat.1004321. [PubMed][CrossRef]
28. Curtis MM, Russell R, Moreira CG, Adebesin AM, Wang C, Williams NS, Taussig R, Stewart D, Zimmern P, Lu B, Prasad RN, Zhu C, Rasko DA, Huntley JF, Falck JR, Sperandio V. 2014. QseC inhibitors as an antivirulence approach for Gram-negative pathogens. mBio 5:e02165-14. doi:10.1128/mBio.02165-14. [PubMed][CrossRef]
29. Lasarre B, Frederie MJ. 2013. Exploiting quorum sensing to confuse bacterial pathogens. Microbiol Mol Biol Rev 77:73–111. [PubMed][CrossRef]
30. Hentzer M, Givskov M. 2003. Pharmacological inhibition of quorum sensing for the treatment of chronic bacterial infections. J Clin Inv 112:1300–1307. [PubMed][CrossRef]
31. Fetzner S. 2014. Quorum quenching enzymes. J Biotechnol 201:2–14. [PubMed][CrossRef]
32. Cegelski L, Marshal GR, Eldridge GR, Hultgren SJ. 2008. The biology and future prospects of antivirulence therapies. Nat Rev Microbial 6:17–27. [PubMed][CrossRef]
33. Anand R, Rai N, Thattai M. 2013. Interactions among quorum sensing inhibitors. PLoS One 8:e62254. doi:10.1371/journal.pone.0062254. [PubMed][CrossRef]
34. Li H, Want L, Ye L, Mao Y, Xie X, Xia C, Chen J, Lu Z, Song J. 2009. Influence of Pseudomonas aeruginosa quorum sensing signal molecule N-(3-oxododecanoyl) homoserine lactose on mast cells. Med Microbiol Immunol 189:113–121. [PubMed][CrossRef]
35. Shang L, Pornpattananangkul D, Hu CM, Huang CM. 2010. Development of nano particles for anti-microbial drug delivery. Curr Med Chem 17:585–594. [PubMed][CrossRef]
36. Palanisamy NK, Ferina N, Amirulhusni AN, Mohd-Zain Z, Hussaini J, Ping LJ, Duairaj R. 2014. Antibiofilm properties of chemically synthesized silver nano particles found against Pseudomonas aeruginosa. J Nanobiotech 12:2. [PubMed][CrossRef]
37. Azam A, Ahmed SA, Oves M, Khan MS, Habib SS, Memic A. 2012. Antimicrobial activity of metal oxide nanoparticles against Gram-positive and Gram-negative bacteria: a comparative study. Int J Nanomed 12:6003–6009. [PubMed][CrossRef]
38. Prahu S, Poulose EK. 2012. Silver nano particles: mechanism of anti-microbial action, synthesis, medical applications, and toxicity effects. Int Nano Lett 2:32. [CrossRef]
39. Barbour ME, Maddocks SW, Wood NJ, Collins AM. 2013. Synthesis, characterization and efficacy of antimicrobial chlorhexidine hexametaphosphate nanoparticles for applications in biomedical materials and consumer products. Int J Nanomed 8:3507–3519. [PubMed][CrossRef]
40. Hook ER, Owen OJ, Bellis CA, Holder JA, O’Sullivan DJ, Barbour ME. 2014. Development of a novel antimicrobial-releasing glass ionomer cement functionalized with chlorhexidine hexametaphosphate nanoparticles. J Nanobiotechnol 12:3–3. [PubMed][CrossRef]
41. Wood NJ, Maddocks SE, Grady HJ, Collins AM, Barbour ME. 2014. Functionalization of ethylene vinyl acetate with antimicrobial chlorhexidine hexametaphosphate nanoparticles. Int J Nanomedicine 9:4145–4152. [PubMed]
42. van Assche E, Van Piyvelde S, Vanderleyden J, Steenackers HP. 2015. RNA-binding proteins involved in post-transcriptional regulation in bacteria. Front Microbiol 6:141. [PubMed][CrossRef]
43. Eyraud A, Tattevin P, Chabelskaya S, Feldon B. 2014. A small RNA controls a protein regulator involved in antibiotic resistance in Staphylococcus aureus. Nucleic Acids Res 42:4892–4905. [PubMed][CrossRef]
44. Molina-Santiago C, Daddaoua A, Gomez-Lozano M, Udaono X, Molin S, Ramos JL. 2015. Differential transcriptional response to antibiotics by Pseudomonas putida DOT-T1E. 17:3251–3262. [PubMed]
45. Libis VK, Bernheim AG, Basier C, Jaramillo-Rivera S, Deyell M, Aghoghogbe I, Atanaskovic I, Bencherif AC, Benony M, Koutsoubelis N, Lochner AC, Marinkovic ZS, Zahra S, Zegman Y, Lindner AB, Wintermute EH. 2014. Silencing of antibiotic resistance in E. coli with engineered phage bearing small regulatory RNAs. ACS Synth Biol 3:1003–1006. [PubMed][CrossRef]
46. Ghosh S, Watson MA, Collins JL. 2007. The relative transcription index: a gene expression based metric for prioritization of drug candidates. Comb Chem High Throughput Screen 10:239–245. [PubMed][CrossRef]
47. Sabir JS, Abu-Zinadah OA, Bora RS, Ahmed MM, Saini KS. 2013. Role of toxicogenomics in the development of safe, efficacious and novel anti-microbial therapies. Infect Disord Drug Targets 13:205–214. [PubMed][CrossRef]
microbiolspec.VMBF-0018-2015.citations
cm/4/2
content/journal/microbiolspec/10.1128/microbiolspec.VMBF-0018-2015
Loading

Citations loading...

Loading

Article metrics loading...

/content/journal/microbiolspec/10.1128/microbiolspec.VMBF-0018-2015
2016-04-08
2017-03-30

Abstract:

Antibiotics are undoubtedly a pillar of modern medicine; their discovery in 1929 revolutionized the fight against infectious disease, instigating a worldwide decline in infection-associated mortality. Throughout the 1930s, 1940s, and 1950s the golden age of antibiotic discovery was underway with numerous new classes of antibiotics identified and brought to market. By 1962 all of our currently known families of antibiotics had been discovered, and it was a widely held belief, that humanity had conquered infectious disease. Despite varying bacterial cellular targets, most antibiotics targeted exponentially multiplying bacteria by interfering with integral processes such as peptidoglycan synthesis or ribosomal activity. The very nature of this targeted approach has driven the emergence of antibiotic-resistant bacteria.

Methods of antibiotic identification relied solely on scientific observation, and while chemical analogues such as amoxicillin, derived from penicillin, continued to be developed, they retained the same mechanisms of action and hence the same bacterial targets. This article describes and discusses some of the emerging novel targets for antimicrobial treatments, highlighting pivotal research on which our ability to continue to successfully treat bacterial infection relies.

Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Supplemental Material

No supplementary material available for this content.

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error